January 12, 2012. NovAliX enters into multi-target intergrated drug discovery collaboration with Teijin Pharma.

Strasbourg, France, January 12, 2011 / b3c newswire - NovAliX SAS announced today that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.

Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise in combination with its comprehensive biophysical technology platform. NovAliX will apply its proprietary Graffinity SPR-based screening technology for the identification of novel chemotypes, and then engage its native nano-MS technology for further characterization of selected small molecule hit structures.

September 13, 2011. NovAliX to collaborate with Fondation Jérôme Lejeune on Down syndrome (trisomy 21).

Strasbourg, France, September 13, 2011/ b3c/ - NovAliX today announces that it has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune.

NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the cystathionine-beta-synthase (CBS). Indeed inhibition of CBS over-expression has been associated with restoration of cognitive impairment in animal models afflicted with trisomy.

August 29, 2011. NovAliX and Galapagos collaborate in osteoarthritis discovery research program.

NovAliX today announces that it has entered into drug discovery collaboration in the field of osteoarthritis with Galapagos.

Under the terms of this agreement NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos. NovAliX will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compoundprotein interactions and then further progress this program to the lead candidate stage by applying its medicinal chemistry and structural biology expertise.

March 30, 2011. Graffinity enters into drug discovery collaboration with Shionogi & Co., Ltd.

Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies (www.novalix.com), announced today that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co., Ltd. Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target..

February 28, 2011. NovAliX Signs Multiyear Services Agreement for Chemistry.

NovAlix today announces that it has services agreement for chemistry with Janssen-Cilag, France, to support its drug discovery efforts.

November 2010. NovAliX acquires a majority interest in Graffinity.

Graffinity's proprietary fragment-based SPR drug discovery technology will be added to NovAliX's integrated chemistry and biophysical capabilities.

January 2010. NovAliX to Buy NMRTec.

NMRTec and NovAliX announced today they have entered into a definitive agreement under which NovAliX will acquire NMRTec. This acquisition allows NovAliX to integrate complementary NMR solutions.

Avril 2009. NovAliX and Graffinity have agreed to provide integrated discovery services for fragment-based drug discovery.

NovAliX and Graffinity (Heidelberg, Germany) have agreed to provide integrated discovery services for FBDD to interested life-science customers. The integration of these complementary capabilities leeds to an unique and unprecedented offering of discovery services using chemical microarrays, label-free SPR imaging of protein ligand-interactions, with subsequent mass-spectrometry full characterization of these interactions along with protein X-ray crystallography and medicinal chemistry.

January 2009. AliX and SOSHO to sign agreement for protein structure determination of intractable targets.

Breakthrough crystallization technology for protein structure determination.

AliX, a NovAliX company and SOSHO, an Osaka university spin-off with expertise in crystallogenesis have announced today that they have entered into an exclusive agreement to supply biopharmaceuticals companies with protein structure determination solutions for difficult targets.

September 2008. Novalyst Discovery and AliX agree to merge. NovAliX launch.

Integrating structural biology and medicinal chemistry.

Following long-standing cooperation, Novalyst Discovery, a chemistry services company, and AliX, a structural biology company, have agreed to merge to create a leading CRO. Together they have launched NovAliX, a multidisciplinary company providing flexible outsourcing solutions for drug discovery and development.